International Journal of Endocrinology / 2017 / Article / Tab 2

Research Article

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes

Table 2

Changes in metabolic parameters after metformin or exenatide treatment.

ParametersExenatide ()Metformin ()

Body weight, kg−5.79 (−8.09 to −3.48)−2.30 (−0.99 to −0.66)0.001
BMI, kg/m2−1.99 (−2.85 to −1.14)−0.83 (−0.99 to −0.66)0.000
TC, mmol/L−0.58 (−1.00 to −0.15)−0.35 (−0.52 to −0.19)0.252
LDL-C, mmol/L−0.17 (−0.42 to 0.08)−0.14 (−0.26 to −0.03)0.900
HDL-C, mmol/L0.06 (−0.02 to 0.13)−0.04 (−0.08 to 0.00)0.358
TG, mmol/L−1.26 (−2.07 to −0.45)−0.03 (−0.31 to 0.26)0.000
FBG, mmol/L−2.62 (−3.89 to −1.35)−2.17 (−2.51to −1.73)0.321
FINS, μIU/mL0.63 (−1.19 to 2.46)−2.03 (−4.50 to −1.52)0.000
HbA1c, %−2.81 (−3.42 to −2.45)−1.44 (−1.67 to −1.21)0.000
HOMA-IR−2.05 (−2.69 to −1.37)−1.88 (−2.23 to −1.06)0.565
HOMA-β33.01 (20.19–45.82)14.03 (6.34–21.72)0.002
HbA1C < 7.0%, n (%)84 (79.5)75 (64.0)0.033

Data are shown as difference (95% CI) versus baseline, except for HbA1C < 7.0%. BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function; HbA1C < 7.0%: the proportion of patients with HbA1c < 7.0% (53 mmol/mol).